Articles tagged with Leukemia
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
Yali Dou, a molecular biologist at Keck School of Medicine of USC, has been elected as an AAAS fellow for her groundbreaking work in understanding leukemia and cancer. Her research on mixed-lineage leukemia proteins has led to the development of potential cancer treatments and a deeper understanding of epigenetics.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Researchers have developed a new approach to improve CAR-T cell therapy effectiveness in treating B-cell Acute Lymphoblastic Leukemia. By creating a TIM-3 decoy, they aim to prevent the tumor from turning off the CAR-T cells, leading to improved anti-leukaemia effectiveness and long-term persistence.
Researchers at Northwestern University have identified a previously unobserved function of Exportin-1, a protein that promotes gene transcription and stimulates stronger gene expression. This discovery could aid in the development of new medications to stymie cancer growth without harming healthy cellular function.
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers at Amsterdam UMC and Moffitt Cancer Center found that contact with CLL cells leads to an energy crisis in T cells, making them unable to proliferate. The study suggests that restoring T cell energy could significantly enhance the effectiveness of current treatments for cancer.
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The study found a significant negative impact of obesity on prognosis, particularly in patients with acute lymphoblastic leukemia and brain tumors.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
A novel study found that the TPMT∗8 allele is associated with reduced metabolism of thiopurine drugs, which can lead to toxicity. The research emphasizes the importance of understanding the function of TPMT∗8 to ensure effective pharmacogenomic testing across all ancestries.
A global clinical trial has shown a significant improvement in disease-free survival rates for children with B-cell acute lymphoblastic leukemia (B-ALL) by combining standard chemotherapy with blinatumomab, an immunotherapy. The study found improved survival rates of up to 97.5% after three years, compared to 90% with chemotherapy alone.
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
Marina Konopleva joins the Eradicating MRD in AML TeamLab to develop new ways to detect and target Minimal Residual Disease. MECCC has developed multiple targeted agents that have become standard of care for older AML patients, and will partner with Break Through Cancer to deepen understanding of MRD drivers.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
Researchers discover a molecular mechanism controlling PAX5, key regulator of B-cell maturation. Increasing SIRT7 activity may boost PAX5 levels in leukemic cells, inducing cell death.
A study of over 700 US counties found a link between childhood leukemia and radon gas levels, including those below the EPA's recommended mitigation threshold. Radon exposure increases the likelihood of leukemia in both boys and girls, according to the research.
A study found that children with Down's syndrome have an elevated number of red blood cells, which increases their risk of developing leukemia. The extra chromosome 21 alters DNA packing and gene regulation, contributing to the development of leukemia.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers found that approximately 60% of genetic changes driving T-ALL cancer cells are non-coding changes, significantly altering the understanding of disease biology. This leads to innovative treatments, including new immunotherapies developed at CHOP and St. Jude.
Researchers discovered novel genetic variations that influence relapse risk in children with standard-risk B-cell acute lymphoblastic leukemia (SR B-ALL). The study highlights the importance of genomic profiling in accurately determining patient risk and tailoring treatment intensity.
Infant leukemia with MLL gene rearrangements is resistant to glucocorticoids due to the production of NG2 protein. This leads to FLT3 activation and inactivation of the glucocorticoid receptor, rendering cells insensitive to treatment. The study provides new targets for drug development and immunotherapy.
Scientists at St. Jude Children's Research Hospital identified age-related differences in B-ALL treatment outcomes, with children being more sensitive to certain drugs. The study suggests that both age and individual genomics must be considered to predict treatment response, leading to the need for tailored treatment strategies.
Researchers found that type II innate lymphoid cells transform after a cancer patient receives stem cells from a donor, preventing an effective immune system rebuilding. This new understanding may lead to better strategies for enhancing immune system recovery post-transplantation.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
A team of researchers from Penn State College of Medicine identified KDR, a tyrosine kinase, as a potential drug target for treating diseases caused by human T-cell leukemia virus type 1 (HTLV-1). By blocking KDR, the viral protein Tax is degraded, leading to cell death and disruption of cancer-causing signaling pathways.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Patients with CLL and NHL who received frequent immunoglobulin G tests had fewer infections, required fewer antimicrobial medications, and higher blood levels of IgG. Increased IgG testing is associated with a lower risk of severe infections, suggesting that clear clinician guidance may save lives.
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
Researchers discovered that T-cell aging is not limited by organismal age, and healthy T cells can proliferate indefinitely. The epigenetic clock of T cells shows that death is not the end, and these cells do not plateau with age, defying traditional notions of cellular aging.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
A new study reveals that a type of childhood leukemia has its roots in fetal development, with chromosomal alterations detected in umbilical cord blood. The findings have important implications for understanding the disease and developing new therapies.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers have developed an approach to 'delete' a diseased blood system while building up a new, healthy one with donor blood stem cells. This process involves targeting specific antibodies coupled to a cytotoxic drug that recognize and destroy diseased blood cells while sparing healthy ones.
A novel andrographolide derivative (AND7) combined with TRAIL enhances anti-cancer effects and improves resistance. The AND7/TRAIL combination promotes apoptosis via P53 and ROS expression.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
Researchers at St. Jude Children's Research Hospital designed a combination therapy to effectively treat relapsed or resistant B-cell leukemia by targeting the developmental stages of cancer cells. The findings revealed that a protein called BCL-2 is a hidden vulnerability in asparaginase-resistant tumor cells.
Researchers found that discontinuing specialist follow-up care for patients with slow-growing CLL had no negative impact on survival, hospital visits or infections. Most patients who ended follow-up developed minor infections treated with antibiotics.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
A genetic variant reducing IKZF1 expression increases B-cell ALL risk in Hispanic/Latino kids, with ancient DNA tracing its emergence ~13,000 years ago from Indigenous American ancestors.
A study from USC Keck School of Medicine reveals a genetic variant on the IKZF1 gene contributing to increased risk of acute lymphoblastic leukemia among Hispanic/Latino children. The variant increases ALL risk by around 1.4 times and may be linked to Indigenous American ancestry, according to researchers.
A large cohort study found that longer durations of exclusive breastfeeding were associated with a lower risk of childhood B-cell precursor-acute lymphoblastic leukemia. The study's results suggest potential biologic mechanisms underlying this association and inform the need for further research on preemptive interventions.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A study by IRB Barcelona and Sant Joan de Déu Hospital reveals three distinct patterns explaining the occurrence of second cancers in children, including a mutational footprint from chemotherapy. The research advances understanding of pediatric cancer and highlights the importance of clinical data sharing.